SRV's net sales in Q2 amounted to EUR 186.3m, slightly above our estimate of EUR 178.
Redeye was a bit surprised by the dip in gross margins in the second quarter.
- Sales and EBITDA in line with ABGSCe - Simplicity and predictability likely to drive limited cons.
Incap upgraded its 2024 full year guidance. Net sales is now guided to grow (previously decline) in ...
Redeye provides a short comment on Ortoma’s Q2 report this morning.
Redeye states that the Q2 report came in above its estimates on both sales and EBITDA.
- Sales -6% y-o-y, -12% vs. ABGSCe - EBIT of SEK 49m, +12% vs.
Redeye provides its initial take on ADDvise’s Q2 2024 report, which came in broadly below our estima...
- Net sales SEK 191m, 3% vs ABGSCe, 2% vs Factset cons.
Redeye retains its positive view on Lagercrantz following a Q1 report in-line with our estimates.
Svedbergs Group posted a solid set of Q2 2024 numbers, with sales coming in-line with our estimates ...
Redeye comments on the Q2 report released earlier this morning.
Redeye states that Enea showed in Q2 that organic growth is here to stay, delivering +14% y/y growth...
Doro delivered better than expected Q2 report on all key metrics.
Cibus' Q2 2024 income from property management (IFPM) was 6% above Infront consensus, but the result...
Redeye raises its forecasts and Base Case following Hexatronic’s Q2 report, showing a solid sequenti...
- Higher sales and gross margin in Q2 - EBITDA revised up 2.
- Q2e: 21% ARR growth and adj. EBITDA of DKK 1.1m - '24e likely to be even more back-end loaded vs.
- Rec. PTP 7% below ABGSCe - CEPS est. +2.7-0.6% for '25-26e due to projects - Share trading at a ~3...
Redeye endorses today’s news that the ETA (“European Thyroid Association”) recommends Emcitate as a ...
